MedTrace Logo

Effectiveness of Upper Quarter Biodex Training

NCT04670861 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-02-21

No results posted yet for this study

Summary

Strength, and proprioception training of upper body following injuries is commonly recommended. However, there are no previous studies investigated the effects of Biodex balance training on the strength, stability and function of the upper quarter. So, the purpose of this study will investigate the effect of Biodex balance training on improving the strength, dynamic stability and function of the upper quarter in young recreational weightlifters.

Conditions

  • Resistance Training

Interventions

PROCEDURE

Upper extremity Biodex balance training

The person assumes the prone plank posture with both hands poisoned in the area assigned for foot placement on the tilting balance platform. Using the four keypads, the person's left hand, left wrist, right hand and right wrist positions are entered into the system using the midline of the hand and the platform grid as reference points. The dot that appears on the position patient screen represents the person's segmental center of gravity. During each trial test, the person should shift his weight to move the cursor from the center along a target path and back as quickly and with a little deviation as possible. The same process is repeated for each of the targets. Target paths activate in a random order.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
25 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2021-03-31
Completion
2021-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04670861 on ClinicalTrials.gov